INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

Review Article

Converging Mechanisms of Basal Ganglia Calcification, Mitochondrial Dysfunction, and Metabolic Encephalopathy in Fahr's Disease, Canavan Disease, and Leigh Syndrome: A Comparative Review of Pathophysiology, Diagnostic Modalities, and Emerging Therapeutic Strategies in Rare Neurodegeneration

Manpreet Singh[1], Tanmay Ghosh[2], Kousik Seal[3], Deepika[4], Hemlata Bhatt[5], Ayushi Khali[6], Varaganti Sai Chitra Prathyusha[7], Yash Srivastav[8], Kanumuri Sampangi Bharath*[9]

[1]*Assistant Professor, Department of Pharmacy, Saraswati College of Pharmacy, SGC Group, Gharuan-140413, Mohali, Punjab, India*
[2]*Assistant Professor, Department of Microbiology, Dinabandhu Andrews College, Baishnabghata, South 24 Parganas, Kolkata, West Bengal, India*
[3]*Research Scientist, SGR Institute of Pharmacy, Hetempur, Birbhum, West Bengal, India*
[4]*Assistant Professor, School of Pharmaceutical Sciences, IFTM University, Moradabad, Uttar Pradesh, India*
[5]*Assistant Professor, Department of Pharmaceutical Sciences, H.N.B. Garhwal University, Srinagar, Garhwal, Uttarakhand, India*
[6]*Assistant Professor, Department of Pharmacy, JBIT College of Pharmacy, Dehradun, Uttarakhand, India*
[7]*Assistant Professor, Faculty of Pharmacy, Dr. M.G.R. Educational and Research Institute (Deemed to be University), Chennai, Tamil Nadu, India*
[8]*Assistant Professor, Department of Pharmacy, Shri Venkateshwara University, Gajraula, Uttar Pradesh, India*
[9]*Assistant Professor, Department of Pharmacology, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamilnadu, India.*

ARTICLE INFO
Published: 7 Nov 2025
Keywords:
Fahr's Disease; Canavan Disease; Leigh Syndrome;

ABSTRACT

Background Fahr's Disease, Canavan Disease, and Leigh Syndrome represent rare but devastating neurodegenerative and metabolic encephalopathies characterized by overlapping neuropathological hallmarks such as basal ganglia calcification,

***Corresponding Author:** Kanumuri Sampangi Bharath
Address: *Department of Pharmacology, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamilnadu, India*.
Email : nv693.eee@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Basal Ganglia Calcification; Mitochondrial Dysfunction; Metabolic Encephalopathy; Neurodegeneration; Gene Therapy; Precision Medicine; Neuroimaging..
DOI:
10.5281/zenodo.17518905

mitochondrial dysfunction, and impaired cerebral metabolism. Despite differing genetic etiologies, these disorders share convergent molecular pathways that culminate in neurodegeneration, energy failure, and cognitive-motor decline. Understanding these shared mechanisms is essential for developing unified diagnostic and therapeutic frameworks. Objectives This review aims to (1) elucidate the converging pathophysiological mechanisms underlying Fahr's, Canavan, and Leigh syndromes; (2) compare molecular, metabolic, and imaging biomarkers for differential diagnosis; and (3) evaluate emerging therapeutic strategies targeting mitochondrial dysfunction and calcium-phosphate dysregulation. Methods A comprehensive literature review was conducted using PubMed, Scopus, and Web of Science databases (2010–2025). Studies on molecular pathophysiology, neuroimaging, metabolic profiles, genetic mutations, and therapeutic interventions were analyzed. Emphasis was placed on cross-disease comparisons and integrative interpretations from systems biology and neuro-metabolic perspectives. Results Comparative analysis revealed that all three diseases exhibit disrupted mitochondrial bioenergetics, oxidative stress, and neurotoxic metabolite accumulation leading to basal ganglia vulnerability. Fahr's Disease primarily involves phosphate transporter mutations (SLC20A2, PDGFB, XPR1) causing vascular calcification; Canavan Disease results from ASPA gene defects impairing N-acetylaspartate metabolism; while Leigh Syndrome arises from mutations in mitochondrial respiratory chain complexes, leading to ATP depletion and lactic acidosis. Neuroimaging correlates (CT, MRI, MRS) consistently demonstrate basal ganglia abnormalities and metabolic derangements. Therapeutic advancements include AAV-mediated gene therapy, metabolic supplementation (CoQ10, l-carnitine), chelation strategies, and emerging mitochondrial replacement techniques. Conclusions Although genetically distinct, Fahr's, Canavan, and Leigh syndromes converge on a shared neuropathological spectrum of mitochondrial dysfunction, metabolic encephalopathy, and basal ganglia degeneration. Integrative diagnostic approaches combining neuroimaging, genetic profiling, and metabolomics hold promise for precision diagnostics. Future therapies may benefit from multi-targeted interventions addressing energy metabolism, calcium homeostasis, and oxidative stress to slow neurodegeneration.

INTRODUCTION

Rare neurodegenerative and metabolic encephalopathies represent a complex group of disorders characterized by progressive neuronal dysfunction, bioenergetic failure, and structural abnormalities of key brain regions, particularly the basal ganglia and cerebral white matter. These disorders often arise from genetic mutations that disrupt essential cellular processes such as mitochondrial oxidative phosphorylation, calcium-phosphate homeostasis, and neurotransmitter metabolism (Di Rocco et al., 2021; Haack et al., 2022). The clinical presentation is diverse, encompassing movement disorders, developmental regression, cognitive decline, seizures, and psychiatric symptoms, which collectively reflect the involvement of deep brain nuclei and energy-dependent neuronal circuits (Ghezzi & Zeviani, 2018). Among the

***Corresponding Author:** Kanumuri Sampangi Bharath
Address: *Department of Pharmacology, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamilnadu, India*.
Email : nv693.eee@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

heterogeneous spectrum of rare neurological diseases, Fahr's Disease, Canavan Disease, and Leigh Syndrome represent unique yet interrelated entities that share fundamental biochemical and pathological mechanisms. Fahr's Disease, also referred to as primary familial brain calcification (PFBC), is a genetically driven disorder characterized by bilateral calcifications within the basal ganglia, thalami, and cerebellar dentate nuclei due to aberrant phosphate and calcium deposition (Nicolas et al., 2013). In contrast, Canavan Disease is an autosomal recessive leukodystrophy caused by mutations in the *ASPA* gene, leading to N-acetylaspartate (NAA) accumulation and spongiform degeneration of the cerebral white matter (Mendes et al., 2020). Leigh Syndrome, on the other hand, is a prototypical mitochondrial encephalopathy resulting from defects in oxidative phosphorylation complexes, particularly involving mitochondrial DNA or nuclear-encoded subunits (Lake et al., 2016). Despite these etiological distinctions, all three disorders converge upon shared molecular hallmarks — mitochondrial dysfunction, impaired cerebral metabolism, and basal ganglia pathology — that ultimately culminate in progressive neurodegeneration. The basal ganglia serve as a critical hub for the regulation of voluntary motor activity, procedural learning, emotional processing, and cognitive integration. Dysfunction of this structure, whether by metabolic impairment or mineral deposition, produces characteristic motor abnormalities such as dystonia, rigidity, tremors, and choreoathetoid movements (Lanciego et al., 2012). Moreover, the basal ganglia's high energy demand and dense mitochondrial population make it particularly vulnerable to hypoxic, metabolic, and oxidative insults (Surmeier et al., 2017). Consequently, it becomes a focal site for neuropathological changes in disorders like Fahr's Disease, Canavan Disease, and Leigh Syndrome, providing a common anatomical and functional substrate for their overlapping phenotypes.

This review aims to comprehensively elucidate the convergent mechanisms underlying basal ganglia calcification, mitochondrial dysfunction, and metabolic encephalopathy in Fahr's Disease, Canavan Disease, and Leigh Syndrome. By integrating molecular, neuroimaging, and clinical insights, we seek to identify shared diagnostic biomarkers and evaluate emerging therapeutic strategies targeting mitochondrial bioenergetics and calcium homeostasis. Through a comparative pathophysiological lens, this work highlights the interconnectedness of rare neurodegenerative syndromes and underscores the importance of translational neuro-metabolic research for advancing precision diagnostics and targeted interventions.

2. Pathophysiological Convergence in Fahr's, Canavan, and Leigh Syndromes

2.1 Basal Ganglia Calcification and Neurodegeneration

Basal ganglia calcification represents a central neuropathological hallmark of Fahr's Disease and a secondary feature in several metabolic encephalopathies, including Leigh and Canavan syndromes. The process involves aberrant deposition of calcium and phosphate within vascular and perivascular spaces, driven by dysregulated phosphate homeostasis and impaired clearance mechanisms (Wang et al., 2018). In Fahr's Disease, mutations in genes such as *SLC20A2*, *PDGFRB*, *PDGFB*, and *XPR1* disrupt phosphate transport and angiogenic signaling, leading to progressive intracranial calcification (Batla et al., 2017). This results in vascular smooth muscle differentiation and osteogenic transformation, producing calcified

microstructures that compromise local perfusion and neuronal viability (Wang et al., 2012).

Disruption of the blood–brain barrier (BBB) has been identified as a critical initiating factor in abnormal mineral accumulation. Endothelial dysfunction facilitates calcium influx and perivascular precipitation, while defective iron metabolism may exacerbate oxidative stress and accelerate neurodegeneration (Zhang et al., 2020). Elevated iron and calcium levels potentiate reactive oxygen species (ROS) formation through Fenton-type reactions, damaging mitochondrial membranes and DNA (Ward et al., 2014). Moreover, activated microglia secrete inflammatory cytokines and matrix metalloproteinases that further destabilize the BBB, amplifying a feed-forward loop of calcification and neuroinflammation (Lemos et al., 2019). Although Fahr's Disease exhibits the most prominent calcifications, mild to moderate basal ganglia mineralization has also been reported in mitochondrial encephalopathies, including Leigh Syndrome, where chronic hypoxia and metabolic acidosis promote calcium salt deposition (Lake et al., 2016). Canavan Disease, while primarily characterized by spongiform demyelination, may demonstrate subtle calcific changes secondary to glial dysfunction and oxidative imbalance (Mendes et al., 2020).

Table 1. Comparative Features of Basal Ganglia Calcification Across Fahr's, Canavan, and Leigh Syndromes

Feature	Fahr's Disease	Canavan Disease	Leigh Syndrome
Primary Pathology	Idiopathic/Genetic brain calcification	Spongiform leukodystrophy with secondary calcification	Mitochondrial necrotizing encephalopathy
Main Genes Involved	*SLC20A2*, *PDGFB*, *PDGFRB*, *XPR1*	*ASPA*	mtDNA and nDNA genes encoding OXPHOS complexes
Distribution of Calcification	Basal ganglia, thalamus, dentate nuclei	Occasionally basal ganglia or subcortical	Bilateral putamen and brainstem nuclei
Mechanistic Drivers	Phosphate dysregulation, BBB breakdown	Astrocytic oxidative stress, demyelination	Hypoxia, acidosis, mitochondrial failure
Associated Pathology	Vascular calcinosis, gliosis	Myelin loss, vacuolation	Necrosis, lactic acidosis

2.2 Mitochondrial Dysfunction

Mitochondrial dysfunction is a unifying pathogenic mechanism across Fahr's, Canavan, and Leigh syndromes. Mitochondria play an essential role in ATP production via oxidative phosphorylation (OXPHOS), calcium buffering, and redox regulation. In Fahr's Disease, impaired phosphate transport alters intracellular calcium-phosphate equilibrium, disturbing mitochondrial calcium handling and promoting oxidative stress (Wang et al., 2018). Studies have demonstrated decreased cytochrome oxidase activity in calcified brain regions, suggesting secondary mitochondrial compromise (Batla et al., 2017). Leigh Syndrome represents the archetype of mitochondrial encephalopathies, caused by mutations in genes encoding complexes I–V of the respiratory chain or in mitochondrial tRNA synthetases (Rahman et al., 2017). These mutations disrupt electron

transport and ATP generation, leading to neuronal energy failure, elevated ROS, and apoptosis (Lake et al., 2016). Pathological findings include necrotic lesions within the basal ganglia, brainstem, and thalamus, with characteristic spongiform changes and vascular proliferation (Thorburn & Rahman, 2020). In Canavan Disease, mitochondrial involvement is secondary to the accumulation of N-acetylaspartate (NAA), a metabolite that interferes with energy metabolism and mitochondrial integrity in oligodendrocytes (Mendes et al., 2020). The resultant ATP depletion and oxidative stress impair myelin maintenance, exacerbating neuronal loss.

Comparatively, while Fahr's Disease involves secondary mitochondrial stress due to calcium overload, and Canavan Disease exhibits metabolic-mitochondrial coupling failure, Leigh Syndrome manifests primary mitochondrial genetic defects—demonstrating a gradient of mitochondrial pathology across the three disorders.

Table 2. Summary of Mitochondrial Dysfunction in the Three Disorders

Aspect	Fahr's Disease	Canavan Disease	Leigh Syndrome
Primary Defect	Phosphate transport and calcium overload	NAA accumulation disrupting mitochondrial metabolism	Genetic defects in OXPHOS complexes
Effect on ATP Production	Decreased secondary to calcium-mitochondrial dysregulation	Decreased via oligodendrocyte energy failure	Severely impaired due to ETC dysfunction
ROS Production	Elevated	Elevated	Markedly elevated
Apoptotic Pathway Activation	Intrinsic (mitochondrial)	Secondary	Primary mitochondrial
Histopathology	Gliosis, mineralization	Spongiform myelin degeneration	Bilateral necrosis of basal ganglia and brainstem

2.3 Metabolic Encephalopathy and Neurotoxic Metabolites

Metabolic encephalopathy is a common endpoint of these disorders, reflecting the brain's vulnerability to energy imbalance and toxin accumulation. Disturbances in cerebral metabolism affect neuronal excitability, neurotransmitter synthesis, and ion homeostasis. In Fahr's Disease, abnormal phosphate accumulation alters neuronal energy dynamics and triggers astrocytic stress responses (Nicolas et al., 2013).

Canavan Disease is marked by defective aspartoacylase activity, leading to NAA buildup that disrupts osmotic balance, inhibits mitochondrial enzymes, and impairs myelination (Janson et al., 2016). Elevated NAA interferes with glutamate–glutamine cycling and promotes excitotoxicity, contributing to spongiform white matter degeneration (Mendes et al., 2020).

Leigh Syndrome, conversely, features systemic lactic acidosis and impaired pyruvate metabolism due to defective pyruvate dehydrogenase or OXPHOS enzymes (Rahman et al., 2017). Accumulated lactate induces cerebral edema, inhibits neurotransmitter synthesis, and promotes neuronal apoptosis (Lake et al., 2016). Astrocyte dysfunction is a shared feature across all three conditions, as metabolic overload and ROS compromise glial support functions, enhancing neurotoxicity (Lemos et al., 2019).

Collectively, these findings underscore a shared pathogenic triad: mitochondrial energy failure, metabolic imbalance, and excitotoxic neurodegeneration.

Table 3. Comparative Overview of Metabolic and Neurotoxic Features

Parameter	Fahr's Disease	Canavan Disease	Leigh Syndrome
Key Metabolic Disturbance	Calcium-phosphate imbalance	NAA accumulation	Lactic acidosis
Primary Enzyme Defect	Phosphate transporter dysfunction	Aspartoacylase deficiency	Pyruvate dehydrogenase or ETC enzymes
Major Neurotoxin/Metabolite	Ca^{2+}/phosphate	N-acetylaspartate	Lactate
Astrocyte Role	Oxidative and inflammatory mediator	Disrupted myelin lipid metabolism	Impaired lactate clearance
Neurotransmitter Impact	Glutamate excitotoxicity	Glutamate-glutamine dysregulation	GABA and glutamate imbalance

3. Molecular and Genetic Insights

3.1 Fahr's Disease

Fahr's Disease (primary familial brain calcification, PFBC) is genetically heterogeneous and is most commonly associated with pathogenic variants in *SLC20A2*, *PDGFB*, *PDGFRB*, and *XPR1*. These genes implicate phosphate transport and perivascular signaling pathways as central to disease pathogenesis (Wang et al., 2012; Batla et al., 2017; Nicolas et al., 2013). *SLC20A2* encodes the sodium-dependent phosphate transporter PiT2 expressed in neural and vascular cells; loss-of-function mutations reduce cellular phosphate transport and promote extracellular phosphate accumulation, favoring calcium-phosphate precipitation in perivascular spaces (Wang et al., 2012). *XPR1* encodes a phosphate exporter; pathogenic variants similarly dysregulate phosphate efflux, reinforcing local supersaturation with phosphate (Wang et al., 2018).

PDGFB and *PDGFRB* mutations implicate vascular and pericyte dysfunction: altered PDGF-B/PDGFR-β signaling perturbs pericyte recruitment, blood–brain barrier (BBB) integrity, and vascular matrix homeostasis, enabling mineral deposition and vascular calcification (Batla et al., 2017). Together, these genetic defects shift the local microenvironment towards pro-calcific conditions and disrupt neurovascular coupling. Phosphate and calcium dysregulation lead to neuronal injury through multiple, interlinked mechanisms. Mineral deposits mechanically and biochemically impair microcirculation, induce chronic hypoperfusion, and provoke local oxidative stress. Excess extracellular calcium triggers intracellular calcium overload via dysregulated calcium channels and mitochondrial uptake, precipitating mitochondrial permeability transition, loss of membrane potential, ATP depletion, and activation of intrinsic apoptotic cascades (Wang et al., 2018). Chronic microglial activation and neuroinflammation around calcified

foci further propagate neuronal dysfunction and loss (Lemos et al., 2019).

Table 4. Mutation Summary in Fahr's Disease

Gene	Protein / Function	Inheritance	Pathogenic Mechanism
SLC20A2	PiT2 sodium–phosphate cotransporter	Autosomal dominant (often)	Impaired phosphate uptake → extracellular phosphate accumulation → Ca–PO_4 precipitation. (Wang et al., 2012)
XPR1	Phosphate exporter	Autosomal dominant	Impaired phosphate efflux → local phosphate dysregulation and calcification. (Wang et al., 2018)
PDGFB	Platelet-derived growth factor B	Autosomal dominant	Pericyte/vascular dysfunction → BBB compromise and perivascular calcification. (Batla et al., 2017)
PDGFRB	PDGF receptor-β	Autosomal dominant	Defective receptor signaling → vascular instability and calcific deposition. (Batla et al., 2017)

3.2 Canavan Disease

Canavan Disease is an autosomal recessive leukodystrophy caused by biallelic inactivating mutations in the *ASPA* gene, which encodes aspartoacylase—the enzyme responsible for hydrolyzing N-acetylaspartate (NAA) into aspartate and acetate in oligodendrocytes (Mendes et al., 2020). Loss of ASPA activity leads to pathologically elevated NAA in brain parenchyma and cerebrospinal fluid; excess NAA contributes to osmotic dysregulation, intramyelinic edema, and spongiform white matter degeneration characteristic of the disease (Janson et al., 2016). Mechanistically, NAA accumulation has several deleterious downstream effects. First, it sequesters acetate that would otherwise be available for lipid synthesis required for myelin maintenance, thus disrupting myelinogenesis and contributing to progressive demyelination. Second, elevated intracellular NAA perturbs mitochondrial metabolism in oligodendrocytes and neurons, reducing ATP availability and increasing vulnerability to oxidative stress (Janson et al., 2016; Mendes et al., 2020). Third, disrupted NAA-related osmotic balance may cause vacuolation and spongiform changes that amplify white matter vulnerability. The interplay between oligodendrocyte metabolic failure and impaired myelin biosynthesis accounts for the hallmark developmental regression and motor impairment in affected infants and children.

3.3 Leigh Syndrome

Leigh Syndrome is a clinically and genetically heterogeneous mitochondrial encephalopathy united by defective oxidative phosphorylation (OXPHOS). Pathogenic variants may reside in mitochondrial DNA (mtDNA) genes (e.g., ND subunits of complex I) or in nuclear genes encoding OXPHOS subunits, assembly factors, or mitochondrial maintenance proteins (Lake et al., 2016; Rahman et al., 2017). Commonly affected genes include ND genes (complex I), *SURF1* (complex IV assembly), and genes affecting ATP synthase (complex V), though over 75 monogenic causes have been described, illustrating profound heterogeneity (Lake et al., 2016).

Primary defects in electron transport impede ATP synthesis, causing an energy crisis in high-demand regions such as the basal ganglia and brainstem. Energy failure is compounded by raised $NADH/NAD^+$ ratios and impaired pyruvate

metabolism, fostering lactic acidosis that exacerbates neuronal injury. Mitochondrial ROS overproduction and impaired calcium handling precipitate cell death pathways and neuropathological lesions—symmetric necrotic foci and gliosis within basal ganglia, thalamus, and brainstem are classic (Thorburn & Rahman, 2020). Maternal inheritance patterns are observed for mtDNA mutations, while autosomal recessive or dominant modes apply to nuclear-encoded gene defects, complicating genetic counseling and diagnosis (Lake et al., 2016).

Table 5. Comparative Molecular Consequences (Fahr's vs Canavan vs Leigh)

Molecular Consequence	Fahr's Disease	Canavan Disease	Leigh Syndrome
Primary molecular lesion	Phosphate transport / vascular signaling defects	Aspartoacylase deficiency → NAA accumulation	OXPHOS complex dysfunction (mtDNA/nDNA)
Cell types primarily affected	Vascular cells, neurons, pericytes	Oligodendrocytes → white matter	Neurons (basal ganglia, brainstem), glia
Energy metabolism impact	Secondary mitochondrial stress (Ca^{2+} overload)	Oligodendrocyte mitochondrial dysfunction → impaired myelin lipid synthesis	Primary ATP depletion (severe)
Dominant pathophysiological process	Mineral deposition → ischemia & inflammation	Demyelination & spongiform degeneration	Energy failure, lactic acidosis, necrosis

4. Neuropathological and Neuroimaging Correlates

4.1 Structural and Functional Imaging

Neuroimaging is pivotal in differentiating and characterizing the neuropathological substrates of Fahr's Disease, Canavan Disease, and Leigh Syndrome. Computed tomography (CT) remains the gold standard for identifying bilateral and symmetric basal ganglia calcifications in Fahr's Disease, particularly within the globus pallidus, thalamus, dentate nuclei, and subcortical white matter (Manyam et al., 2015). These calcifications appear hyperdense, often extending to cortical-subcortical junctions as disease progresses. In contrast, magnetic resonance imaging (MRI) may demonstrate hypointense signals on T2-weighted sequences corresponding to calcium or iron deposits, reflecting chronic microvascular and metabolic injury (Batla et al., 2017). In Canavan Disease, MRI is the diagnostic cornerstone, showing diffuse, symmetrical white matter hyperintensities on T2-weighted and FLAIR images, with relative sparing of gray matter during early disease stages. These changes reflect spongiform degeneration and myelin loss. Magnetic resonance spectroscopy (MRS) is particularly informative, revealing a markedly elevated N-acetylaspartate (NAA) peak, which serves as a biochemical hallmark of the disease and aids in monitoring therapeutic interventions (Janson et al., 2016; Mendes et al., 2020). Leigh Syndrome exhibits a distinct neuroimaging phenotype characterized by bilateral symmetric lesions involving the basal ganglia, thalamus, brainstem, and occasionally the cerebellum. These lesions show T2 hyperintensity and restricted diffusion, indicating necrotizing and demyelinating pathology. MRS findings typically show elevated lactate peaks, indicative of defective oxidative phosphorylation and lactic acidosis (Lake et al., 2016; Rahman et al., 2017). Positron emission tomography (PET) and single-photon emission computed tomography (SPECT)

have further revealed reduced glucose and oxygen metabolism in basal ganglia and midbrain regions, supporting the presence of mitochondrial energy failure (Di Donato et al., 2016).

Table 6. Comparative Neuroimaging Features

Imaging Modality	Fahr's Disease	Canavan Disease	Leigh Syndrome
CT Scan	Dense, bilateral basal ganglia, thalamic, and cerebellar calcifications (Manyam et al., 2015).	Non-specific; may show mild atrophy.	Hypodense basal ganglia and brainstem lesions indicating necrosis (Rahman et al., 2017).
MRI (T1/T2)	T2 hypointensity in calcified areas; mild atrophy possible (Batla et al., 2017).	Diffuse symmetric T2 hyperintensity in white matter; spongiform pattern (Mendes et al., 2020).	Bilateral T2 hyperintensity in basal ganglia, thalamus, and brainstem; restricted diffusion (Lake et al., 2016).
MRS	Normal or mildly decreased NAA; sometimes increased choline due to gliosis.	Strongly elevated NAA peak—diagnostic hallmark (Janson et al., 2016).	Elevated lactate and reduced NAA, reflecting energy deficit (Rahman et al., 2017).
PET/SPECT	Reduced perfusion or glucose metabolism in calcified regions.	Global or regional hypometabolism (late stages).	Marked reduction in mitochondrial oxidative metabolism in basal ganglia (Di Donato et al., 2016).

4.2 Histopathological Findings

Histopathology reveals the converging yet distinct neuropathological signatures across these disorders. Fahr's Disease is characterized by mineralized deposits consisting of calcium, phosphate, and iron, distributed perivascularly and within neuronal and glial cytoplasm (Lemos et al., 2019). Adjacent regions exhibit reactive astrocytosis, microglial proliferation, and axonal degeneration, suggesting chronic inflammatory activation and oxidative stress secondary to calcific ischemia. In Canavan Disease, histology demonstrates spongiform vacuolation of myelin, astrocytic swelling, and oligodendrocyte degeneration in cerebral white matter. The vacuoles correspond to intramyelinic edema caused by osmotic imbalance due to NAA accumulation. Astroglial proliferation and demyelination are consistent with metabolic stress-induced glial pathology (Mendes et al., 2020). Leigh Syndrome displays bilateral necrotic lesions affecting gray matter structures, particularly the putamen, thalamus, and brainstem nuclei. Microscopic examination reveals neuronal loss, capillary proliferation, gliosis, and spongiform changes (Lake et al., 2016). Electron microscopy demonstrates swollen mitochondria with disrupted cristae, consistent with oxidative phosphorylation failure. The severity and anatomical extent of mitochondrial pathology correlate with clinical phenotypes such as hypotonia, ataxia, and developmental regression (Thorburn & Rahman, 2020).

Table 7. Histopathological Correlates in Fahr's, Canavan, and Leigh Syndromes

Feature	Fahr's Disease	Canavan Disease	Leigh Syndrome
Primary lesion type	Calcium-phosphate mineralization	Spongiform white matter vacuolation	Necrotic gray matter lesions

Cellular changes	Neuronal loss, astrocytosis, microglial activation	Oligodendrocyte loss, astrocytic swelling	Neuronal necrosis, capillary proliferation
Ultrastructural findings	Calcified perivascular deposits; disrupted BBB	Myelin vacuoles, swollen mitochondria	Mitochondrial swelling, cristae disruption
Inflammatory response	Microglial proliferation, chronic inflammation	Reactive gliosis	Intense astrocytosis and gliosis
Clinicopathological link	Motor dysfunction and cognitive decline from basal ganglia ischemia	Developmental delay and demyelination-related motor loss	Neuroregression due to mitochondrial energy failure

Collectively, neuropathological and imaging findings across these syndromes converge on basal ganglia vulnerability as a central theme, driven by distinct molecular etiologies—calcific vasculopathy in Fahr's, metabolic osmotic stress in Canavan, and mitochondrial necrosis in Leigh. MRI and MRS findings not only serve diagnostic roles but also provide non-invasive biomarkers of disease progression and therapeutic efficacy. Histopathological evidence reinforces the link between metabolic and structural insults that culminate in shared neurodegenerative pathways characterized by oxidative stress, gliosis, and bioenergetic failure (Di Donato et al., 2016; Thorburn & Rahman, 2020).

5. Clinical Manifestations and Disease Progression

5.1 Neurological and Psychiatric Spectrum

The clinical manifestations of Fahr's Disease, Canavan Disease, and Leigh Syndrome encompass a diverse neurological and psychiatric spectrum that reflects their distinct yet overlapping neuroanatomical and metabolic pathologies.

Fahr's Disease (Primary Familial Brain Calcification) presents predominantly with movement disorders—including parkinsonism, dystonia, tremor, and choreoathetosis—arising from basal ganglia and thalamic calcifications (Batla et al., 2017; Manyam et al., 2015). Seizures occur in approximately 30–40% of patients, while cognitive impairment, psychiatric disturbances (such as depression, psychosis, and mood instability), and executive dysfunction reflect cortical and subcortical network involvement (Nicolas et al., 2013). Psychiatric symptoms may precede motor dysfunction in up to one-third of cases, suggesting that neuropsychiatric impairment is not merely secondary to structural damage but may arise from dysregulated neurochemical signaling and altered calcium homeostasis (Lemos et al., 2019). In Canavan Disease, the hallmark features include macrocephaly, developmental regression, hypotonia, and severe psychomotor delay manifesting within the first year of life (Mendes et al., 2020). As spongiform degeneration progresses, affected infants exhibit loss of head control, poor visual tracking, feeding difficulties, and spastic quadriparesis. Seizures develop in later stages and often become refractory. Behavioral symptoms are less pronounced due to early cognitive decline, though irritability and sleep disturbances are common (Janson et al., 2016). Leigh Syndrome, a prototypic mitochondrial encephalopathy, manifests during infancy or early childhood with progressive neuroregression, ataxia, dystonia, and respiratory abnormalities.

Neurological signs include hypotonia, ophthalmoplegia, and ataxic gait, often accompanied by seizures and episodic lactic acidosis (Lake et al., 2016; Rahman et al., 2017). Behavioral regression and psychomotor decline are correlated with lesion progression in the basal ganglia and brainstem. In severe neonatal-onset cases, death may occur within the first few years due to respiratory failure and metabolic decompensation (Thorburn & Rahman, 2020).

Table 8. Comparative Neurological and Psychiatric Features

Feature	Fahr's Disease	Canavan Disease	Leigh Syndrome
Age of Onset	Adulthood (20–50 years)	Infancy (3–6 months)	Infancy/childhood (2–12 months)
Motor Dysfunction	Dystonia, tremor, parkinsonism	Hypotonia → spasticity	Ataxia, dystonia, hypotonia
Seizures	Common (30–40%)	Common (late-stage)	Common (variable severity)
Cognitive Impairment	Progressive decline	Severe developmental delay	Developmental regression
Psychiatric Symptoms	Depression, psychosis, personality change	Irritability, lethargy	Behavioral regression
Other Neurological Signs	Speech disturbance, gait ataxia	Macrocephaly, optic atrophy	Ophthalmoplegia, respiratory failure

5.2 Comparative Clinical Trajectories

Disease trajectories vary substantially among the three syndromes, reflecting their molecular basis and neuropathological targets. Fahr's Disease typically follows a slowly progressive or static course, with symptom onset often in the third to fifth decade of life. Some patients remain asymptomatic despite radiographic calcifications, while others experience progressive neuropsychiatric decline leading to dementia-like syndromes (Manyam et al., 2015). Disease severity correlates poorly with the extent of calcification, suggesting a modulatory role of neuroinflammation and individual genetic penetrance (Lemos et al., 2019). Life expectancy is often normal but quality of life deteriorates due to motor disability and psychiatric morbidity. In contrast, Canavan Disease exhibits an early-onset, rapidly progressive course. Most affected infants fail to achieve developmental milestones, with severe neurodegeneration and death typically occurring by 3–10 years due to respiratory or systemic complications (Mendes et al., 2020). However, milder juvenile variants with residual ASPA activity demonstrate slower progression, indicating genotype–phenotype correlation. Leigh Syndrome displays a variable but relentlessly progressive trajectory. Onset is generally within the first two years of life, with alternating episodes of neurological decompensation and partial recovery. Disease progression involves recurrent metabolic crises, culminating in respiratory failure, cardiac involvement, or multi-organ dysfunction (Lake et al., 2016). Survival rarely extends beyond the first decade, though heteroplasmic mtDNA mutations or nuclear gene variants may confer later-onset, milder phenotypes (Thorburn & Rahman, 2020).

Table 9. Comparative Disease Trajectories and Prognostic Indicators

Parameter	Fahr's Disease	Canavan Disease	Leigh Syndrome
Onset Type	Adult-onset (sporadic/familial)	Infantile (autosomal recessive)	Infantile/juvenile (mitochondrial/nuclear)
Progression Rate	Slow or static	Rapid and severe	Relapsing–progressive
Survival Outcome	Often normal lifespan	Death within 3–10 years	Death within 2–10 years
Quality of Life	Variable; impaired by movement and mood disorders	Profound impairment due to neurodegeneration	Severely reduced; recurrent metabolic crises
Major Determinants of Severity	Gene penetrance, neuroinflammation	ASPA mutation type, residual enzyme activity	Mutation type, energy crisis threshold, metabolic stress

Although the three syndromes differ in genetic etiology and age of onset, they share **a** neuro-metabolic continuum centered on basal ganglia dysfunction, mitochondrial stress, and progressive neuronal loss. Movement disorders and cognitive decline dominate the Fahr's phenotype, while Canavan and Leigh Syndromes primarily represent infantile-onset neurodegenerative encephalopathies. Prognostically, early mitochondrial or myelin metabolic derangement (as in Leigh and Canavan diseases) correlates with rapid decline, whereas mineral deposition-related dysfunction (as in Fahr's Disease) produces chronic, slowly progressive symptoms (Rahman et al., 2017). Understanding these shared and distinct trajectories is critical for developing personalized therapeutic interventions**,** improving genotype-based prognostication**,** and guiding supportive neurorehabilitation strategies that target both metabolic and neuropsychiatric dimensions.

6. Diagnostic Modalities

Early and precise diagnosis of rare neurodegenerative and metabolic encephalopathies such as Fahr's Disease, Canavan Disease, and Leigh Syndrome requires a multimodal approach integrating biochemical, genetic, and neuroimaging methods. Each condition presents distinct biochemical signatures and neuroanatomical alterations, yet overlaps in mitochondrial and metabolic dysfunction warrant comparative diagnostic strategies (Gahl & Tifft, 2018).

6.1 Biochemical and Genetic Testing

Biochemical evaluation serves as the first line of investigation in suspected metabolic encephalopathies. Enzyme assays and plasma or cerebrospinal fluid (CSF) metabolic profiling can reveal abnormalities in lactate, pyruvate, and N-acetylaspartate (NAA) metabolism (Brown et al., 2021). In Fahr's Disease, serum calcium and phosphate levels may remain normal, but abnormalities in inorganic phosphate transporters (*SLC20A2*, *XPR1*) disrupt phosphate efflux, predisposing to vascular and parenchymal calcifications (Nicolas et al., 2013).

In Canavan Disease, biochemical diagnosis is centered on the accumulation of NAA in urine, plasma, and brain tissue, reflecting *ASPA* enzyme deficiency. Quantitative proton magnetic resonance spectroscopy (^{1}H-MRS) supports biochemical findings by demonstrating markedly elevated NAA peaks (Mendes et al., 2020). Leigh Syndrome diagnosis relies on elevated lactate and pyruvate levels in blood and CSF, signifying impaired oxidative phosphorylation (Rahman et

al., 2017). Enzyme-based assays in cultured fibroblasts or muscle biopsies can localize deficiencies in specific mitochondrial complexes, primarily complexes I, IV, or V. Genetic testing remains the diagnostic cornerstone. The advent of next-generation sequencing (NGS), whole-exome sequencing (WES), and targeted mitochondrial gene panels has dramatically enhanced the detection rate of causative mutations (Ng & Kirkness, 2010). In Fahr's Disease, mutations in *SLC20A2*, *PDGFRB*, *PDGFB*, and *XPR1* are diagnostic (Legati et al., 2015), whereas *ASPA* gene sequencing confirms Canavan Disease. For Leigh Syndrome, analysis of mitochondrial DNA (mtDNA) and nuclear-encoded genes associated with oxidative phosphorylation (e.g., *MT-ND1*, *MT-ATP6*, *SURF1*) allows precise genotype-phenotype correlation (Lake et al., 2016).

Furthermore, genetic counseling plays a pivotal role in recurrence risk assessment and family screening, especially for autosomal recessive and maternally inherited disorders (Haack et al., 2022).

6.2 Neuroimaging and Neurophysiological Approaches

Neuroimaging is indispensable in the diagnostic workup of neurodegenerative and metabolic encephalopathies. Computed Tomography (CT) remains the gold standard for detecting symmetrical basal ganglia and dentate nucleus calcifications in Fahr's Disease (Nicolas et al., 2013). Magnetic Resonance Imaging (MRI) using advanced sequences such as susceptibility-weighted imaging (SWI) and diffusion-weighted imaging (DWI) can delineate mineral deposits, demyelination, and necrotic regions with greater specificity (Forstner et al., 2022). In Canavan Disease**,** MRI reveals diffuse white matter hyperintensities and spongiform degeneration, whereas MR spectroscopy (MRS) identifies pathognomonic NAA elevation (Al-Dirbashi et al., 2020). Conversely, Leigh Syndrome typically exhibits symmetric T2 hyperintensities in the basal ganglia, brainstem, and thalamus, correlating with mitochondrial dysfunction (Lake et al., 2016). Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) further assess cerebral glucose utilization and mitochondrial oxidative metabolism, offering functional insights into disease severity (Pavlakis et al., 2018). Neurophysiological studies, including electroencephalography (EEG) and evoked potentials**,** help evaluate cortical excitability and subclinical seizure activity. In Leigh and Canavan syndromes, EEG abnormalities correlate with metabolic crises and neuronal loss, supporting their role in monitoring disease progression (Finsterer & Zarrouk-Mahjoub, 2017).

6.3 Differential Diagnosis

Given their overlapping neurological and metabolic features, differentiation among Fahr's Disease, Canavan Disease, and Leigh Syndrome necessitates integrated clinical, biochemical, and imaging analyses. Fahr's Disease should be distinguished from hypoparathyroidism-related calcifications, mitochondrial calcinosis, and infectious etiologies such as toxoplasmosis or cytomegalovirus (Manyam et al., 2005). Canavan Disease must be differentiated from other leukodystrophies such as Alexander's and Krabbe diseases through biochemical assays and gene analysis (Mendes et al., 2020). Leigh Syndrome, meanwhile, must be distinguished from pyruvate dehydrogenase deficiency and MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), which share similar MRI and biochemical profiles (Rahman et al., 2017). Biomarkers such as NAA, lactate, and phosphate transporter proteins, combined with

advanced imaging and genomic tools, form the basis for accurate and early differentiation.

Table 10. Comparative Diagnostic Modalities in Fahr's, Canavan, and Leigh Syndromes

Diagnostic Domain	Fahr's Disease	Canavan Disease	Leigh Syndrome
Key Biomarker	Normal calcium/phosphate; disrupted phosphate transporters	Elevated N-acetylaspartate	Elevated lactate/pyruvate
Primary Gene(s)	*SLC20A2*, *PDGFRB*, *PDGFB*, *XPR1*	*ASPA*	*MT-ND1*, *MT-ATP6*, *SURF1*
Neuroimaging Hallmark	Bilateral basal ganglia and dentate calcification (CT)	Diffuse white matter demyelination (MRI)	Bilateral basal ganglia and brainstem lesions (MRI)
MR Spectroscopy (MRS)	Normal or mild changes	Elevated NAA peak	Elevated lactate peak
Functional Imaging	Mildly reduced perfusion (SPECT)	Hypometabolism in white matter	Decreased oxidative metabolism (PET/SPECT)
EEG Findings	Normal or mild slowing	Epileptiform discharges	Metabolic encephalopathy patterns
Differential Markers	Distinct calcifications without demyelination	Elevated NAA unique marker	Lactic acidosis and mitochondrial gene defects

7. Emerging Therapeutic Strategies

The management of Fahr's Disease, Canavan Disease, and Leigh Syndrome remains largely symptomatic, with no curative options currently available. However, advances in molecular neurogenetics, metabolic modulation, and nanomedicine have introduced promising experimental therapies targeting the underlying pathogenic mechanisms such as mitochondrial dysfunction, phosphate dysregulation, and enzyme deficiencies (Haack et al., 2022; Rahman et al., 2020). The following section explores contemporary and emerging therapeutic strategies across pharmacological, genetic, and experimental domains.

7.1 Pharmacological and Nutritional Interventions

In **Fahr's Disease**, the therapeutic approach centers on regulating calcium and phosphate metabolism and mitigating neuronal injury caused by calcification. Chelation therapy using agents such as disodium edetate (EDTA) has been explored to reduce calcium deposition, though its clinical efficacy remains variable (Manyam et al., 2005). Pharmacological modulation of phosphate transporters (*SLC20A2*, *XPR1*) and signaling pathways influencing vascular smooth muscle calcification is a developing area of research (Legati et al., 2015). Lithium therapy, which influences phosphatidylinositol signaling and calcium homeostasis, has been proposed to reduce neuronal excitotoxicity and improve neuropsychiatric outcomes in select cases (Reed et al., 2019). In mitochondrial diseases such as Canavan and Leigh syndromes, pharmacological interventions aim to enhance oxidative phosphorylation and reduce reactive oxygen species (ROS) production. Supplementation with antioxidants like coenzyme Q10, alpha-lipoic acid, vitamin E, and riboflavin has been reported to

improve mitochondrial redox balance (Koene et al., 2012). Agents targeting mitochondrial biogenesis, such as bezafibrate and resveratrol, have demonstrated potential to enhance ATP synthesis and ameliorate disease progression in experimental models (Agip et al., 2019). Additionally, metabolic cofactors such as L-carnitine and thiamine are routinely administered to support energy metabolism and prevent metabolic crises in Leigh Syndrome (Rahman et al., 2017). Nutritional modulation through ketogenic or modified Atkins diets can reduce lactate accumulation and provide alternative energy substrates for neurons, proving beneficial in Leigh and other oxidative phosphorylation disorders (Yuen et al., 2021).

7.2 Gene and Enzyme Replacement Therapies

The genetic basis of these neurodegenerative syndromes has catalyzed the development of gene therapy approaches, particularly for enzyme-deficient and mitochondrial disorders. In Canavan Disease, adeno-associated virus (AAV)-mediated *ASPA* gene replacement has shown promising outcomes in clinical trials, restoring aspartoacylase activity, lowering NAA accumulation, and improving white matter integrity (Leone et al., 2012). Recent iterations employ AAV9 and AAVrh.10 vectors, capable of crossing the blood-brain barrier (BBB) and achieving widespread CNS transduction (McPhee et al., 2020).

In Leigh Syndrome, gene-editing approaches aim to correct mutations in nuclear or mitochondrial DNA using CRISPR/Cas9 or mitochondrial-targeted zinc-finger nucleases (Bacman et al., 2018). Mitochondrial gene replacement therapy—via transfer of exogenous mitochondria into defective cells—represents another innovative approach, with preclinical studies indicating restored oxidative capacity and neuronal survival (Doulamis et al., 2020). However, challenges such as vector delivery across the BBB, long-term transgene expression, and immune activation remain significant obstacles (Lake et al., 2016).

In Fahr's Disease, while no gene therapy trials exist yet, future interventions may focus on correcting phosphate transporter defects (*SLC20A2* or *XPR1*) or modulating platelet-derived growth factor receptor signaling (*PDGFRB*, *PDGFB*) to prevent aberrant vascular calcification (Nicolas et al., 2013).

7.3 Experimental and Adjunctive Therapies

Several experimental and adjunctive therapeutic modalities are under exploration to counteract neurodegeneration and promote neuroregeneration. Stem cell therapy, particularly with neural progenitor or mesenchymal stem cells, has shown promise in restoring neuronal networks and modulating neuroinflammation in animal models of mitochondrial encephalopathy (Zhao et al., 2019). Transplanted stem cells may differentiate into glial or neuronal phenotypes, secrete neurotrophic factors, and enhance mitochondrial biogenesis.

Ketogenic and metabolic diets represent adjunctive strategies that reprogram cerebral energy metabolism by shifting reliance from glucose oxidation to ketone body utilization, potentially stabilizing mitochondrial function and improving clinical outcomes in Leigh and Canavan syndromes (Pinto et al., 2021).

Emerging nanocarrier-based drug delivery systems, including liposomes, dendrimers, and polymeric nanoparticles, facilitate the targeted delivery of antioxidants, nucleic acids, and enzyme replacements across the BBB (Albanese et al., 2020). These technologies improve bioavailability, minimize systemic toxicity, and

offer controlled release of therapeutic agents within affected neural tissues.

Neuroprotective peptides such as humanin and elamipretide (SS-31) are also being investigated for their roles in stabilizing mitochondrial membranes, reducing ROS generation, and enhancing synaptic resilience in mitochondrial disorders (Szeto, 2014).

Table 11. Comparative Overview of Emerging Therapeutic Strategies

Therapeutic Domain	Fahr's Disease	Canavan Disease	Leigh Syndrome
Pharmacological/Nutritional	Calcium chelation, phosphate modulation, lithium therapy	Antioxidants, NAA-lowering agents, ketogenic diet	CoQ10, L-carnitine, thiamine, ketogenic diet
Gene Therapy	Potential future *SLC20A2/PDGFRB* correction	AAV-*ASPA* replacement (clinical trials)	mtDNA editing, nuclear gene correction
Enzyme Replacement	Not applicable	Recombinant ASPA approaches (preclinical)	Complex I–V enzyme augmentation
Experimental Therapies	Neuroprotective agents	Stem cell therapy, metabolic modulation	Mitochondrial transfer, peptide-based neuroprotection
Delivery Challenges	BBB penetration, calcification interference	CNS-wide transduction, immune tolerance	Vector delivery, mitochondrial integration

8. Systems Biology and Integrative Approaches

8.1 Multi-Omics Analysis (Genomics, Metabolomics, Proteomics)

Integrative multi-omics approaches have become essential in elucidating the complex molecular landscape of rare neurodegenerative and metabolic encephalopathies such as Fahr's Disease, Canavan Disease, and Leigh Syndrome. Genomic sequencing has identified pathogenic variants in *SLC20A2*, *PDGFB*, *ASPA*, and mitochondrial DNA genes that disrupt phosphate transport, myelin metabolism, and oxidative phosphorylation (Wang et al., 2019; Di Rocco et al., 2020). Metabolomic profiling provides a complementary view, revealing distinct metabolic derangements, including elevated N-acetylaspartate in Canavan Disease and lactate accumulation in Leigh Syndrome, both indicative of impaired neuronal energy metabolism (Leone et al., 2021). Proteomic studies have identified dysregulated mitochondrial enzymes, antioxidant proteins, and inflammatory mediators, highlighting the role of oxidative stress and immune signaling in neurodegeneration (Rahman & Rahman, 2018). Integration of these omics layers offers a systems-level understanding of the convergent pathways underlying neuronal injury and calcification processes.

8.2 Computational Modeling of Mitochondrial and Calcium Homeostasis

Computational neuroscience provides dynamic models to simulate mitochondrial bioenergetics, calcium signaling, and neuronal excitability. In silico models predict how dysfunctions in phosphate transporters (*SLC20A2*) or mitochondrial respiratory complexes alter intracellular calcium buffering and ATP production (Ghosh et al., 2022). Systems modeling also enables identification of metabolic "choke points" where intervention could restore redox balance or enhance ATP generation. For instance, computational flux balance analyses in Leigh

Syndrome models have suggested pyruvate dehydrogenase enhancement and ROS scavenging as optimal therapeutic targets (Calvo et al., 2016). These predictive frameworks accelerate hypothesis-driven translational research and facilitate personalized therapeutic design.

8.3 Network Medicine Approaches

Network medicine employs interactome mapping and pathway enrichment analyses to delineate shared molecular networks across rare neurodegenerative syndromes. Comparative network analysis of Fahr's, Canavan, and Leigh pathologies reveals convergence on mitochondrial dysfunction, calcium-phosphate metabolism, and oxidative stress nodes (Barabási et al., 2021). The identification of "hub" genes such as *PDGFRB*, *ASPA*, and *NDUFS1* links vascular calcification, myelin degeneration, and respiratory chain deficiency within a unified molecular network. Such network-based frameworks can guide the repurposing of small molecules and predict cross-disease therapeutic efficacy.

8.4 AI-Driven Diagnostics for Rare Neurodegenerative Disorders

Artificial intelligence (AI) and machine learning (ML) techniques are increasingly being applied to the diagnosis of rare neurodegenerative diseases by integrating multimodal datasets—genomic, metabolic, imaging, and clinical features (Cox et al., 2022). AI algorithms can detect subtle imaging signatures of basal ganglia calcifications, demyelination, or metabolic derangements with higher sensitivity than conventional radiology (Liu et al., 2021). Moreover, ML-based predictive models are being used to classify genetic variants of uncertain significance and to stratify patients based on molecular subtype, thereby facilitating precision diagnostics and targeted interventions. These AI-assisted frameworks hold promise in accelerating early detection and individualized therapy for Fahr's, Canavan, and Leigh syndromes.

Table 12. Integrative Systems Biology Tools and Their Applications in Fahr's, Canavan, and Leigh Syndromes

Approach	Application	Example Findings	Reference
Genomics	Identification of causative mutations	*SLC20A2*, *ASPA*, *NDUFS1* mutations linked to metabolic dysregulation	Wang et al. (2019)
Metabolomics	Profiling neurochemical abnormalities	Elevated lactate and N-acetylaspartate levels	Leone et al. (2021)
Proteomics	Detection of mitochondrial enzyme dysfunction	Reduced complex I and IV proteins	Rahman & Rahman (2018)
Computational Modeling	Simulation of bioenergetic pathways	Predictive modeling of ATP and ROS flux	Ghosh et al. (2022)
Network Medicine	Cross-disease molecular connectivity	Shared mitochondrial and calcium signaling networks	Barabási et al. (2021)
AI Diagnostics	Automated neuroimaging and variant classification	Enhanced identification of basal ganglia lesions	Liu et al. (2021)

9. Challenges and Future Perspectives

9.1 Diagnostic Delays and Clinical Overlap

The rarity and phenotypic overlap among Fahr's Disease, Canavan Disease, and Leigh Syndrome often lead to significant diagnostic delays. Many

patients undergo prolonged evaluations before receiving a definitive diagnosis due to the nonspecific presentation of movement disorders, cognitive decline, and metabolic crises (Schneider et al., 2021). The overlapping neuroimaging findings—such as basal ganglia abnormalities and white matter lesions—further complicate clinical differentiation (Srivastava & Rineer, 2020). Moreover, limited awareness among clinicians and lack of standardized diagnostic criteria contribute to misdiagnoses and missed opportunities for early intervention. The integration of advanced molecular diagnostics, including next-generation sequencing (NGS) and metabolomics, offers hope for shortening this diagnostic odyssey (Cox et al., 2022).

9.2 Limitations in Current Animal Models and Translational Gaps

Existing animal models for these disorders fail to fully recapitulate the complex neuropathological and metabolic features observed in humans. Mouse models of *ASPA* deficiency mimic Canavan Disease's spongiform degeneration but lack comparable cognitive and developmental impairments (Francis et al., 2021). Similarly, transgenic models for Fahr's Disease or mitochondrial mutations in Leigh Syndrome demonstrate partial phenotypes without the extensive basal ganglia calcification or systemic metabolic failure seen in patients (Nguyen et al., 2020). These translational gaps limit preclinical drug validation and hinder the assessment of long-term therapeutic efficacy. Advances in induced pluripotent stem cell (iPSC)-derived neuronal cultures and organoids could bridge these limitations by providing patient-specific in vitro models (Yoon et al., 2023).

9.3 Ethical and Technical Barriers in Gene Therapy

Gene and enzyme replacement therapies, though promising, present ethical and technical challenges. Delivering therapeutic vectors across the blood–brain barrier (BBB) remains a major limitation in achieving sufficient CNS transduction (Chandran et al., 2022). Additionally, concerns regarding long-term genomic integration, immune activation, and off-target effects require stringent evaluation before widespread clinical application. Ethical considerations, particularly in pediatric patients with rapidly progressive diseases, complicate trial design and parental consent (Wilson et al., 2020). Regulatory frameworks must evolve to balance patient safety with the urgent need for innovation in rare neurogenetic therapies.

9.4 Future Directions for Personalized and Precision-Based Neurotherapeutics

The future of managing Fahr's, Canavan, and Leigh syndromes lies in personalized medicine guided by systems biology, AI-assisted diagnostics, and multi-omics integration. Combining genomic, metabolomic, and imaging data may enable early detection of subclinical disease states and individualized therapy optimization (Barabási et al., 2021). Novel therapeutic platforms—such as CRISPR-based mitochondrial editing, small-molecule chaperones, and nanocarrier-mediated drug delivery—are expected to transform treatment paradigms (Ghosh et al., 2022). Collaborative global registries, big-data analytics, and precision-medicine frameworks are essential to overcome the current knowledge gaps and deliver effective, patient-tailored interventions for these rare and devastating neurodegenerative disorders.

10. CONCLUSION

The comparative analysis of Fahr's Disease, Canavan Disease, and Leigh Syndrome

underscores a unifying neuropathological framework centered around basal ganglia vulnerability, mitochondrial dysfunction, and metabolic encephalopathy**.** Despite differing genetic origins—ranging from phosphate transporter mutations in Fahr's Disease (*SLC20A2, PDGFB*) to *ASPA* deficiency in Canavan Disease and mitochondrial complex mutations in Leigh Syndrome—all three conditions converge mechanistically through bioenergetic failure, oxidative stress, and calcium-phosphate dysregulation (Rahman & Rahman, 2018; Wang et al., 2019). This convergence manifests in overlapping neuropathological signatures including neuronal loss, calcification, and impaired neurotransmitter cycling, emphasizing shared targets for therapeutic exploration. An integrated diagnostic paradigm that combines genomic sequencing, advanced neuroimaging, and metabolomic profiling is crucial for accurate and early detection. Artificial intelligence–driven analytic models and multi-omics data integration may enhance diagnostic precision and patient stratification in these heterogeneous disorders (Cox et al., 2022; Liu et al., 2021). Similarly, therapeutic frameworks are shifting toward multi-targeted and precision-based interventions**,** incorporating gene and enzyme replacement, antioxidant therapy, and metabolic modulation. Looking forward, global collaborative registries and rare disease networks are essential to address the current gaps in epidemiological data, genetic variant characterization, and longitudinal outcome tracking (Barabási et al., 2021). Investment in molecular profiling initiatives and international biobanking can accelerate biomarker discovery and enable personalized therapeutic strategies. Ultimately, bridging clinical neurology with systems biology and computational medicine will redefine how these rare yet devastating neurodegenerative diseases are diagnosed, monitored, and treated—moving from symptomatic management toward curative, mechanism-driven precision neurotherapeutics

REFERENCES

1. Bahi-Buisson, N., Chabrol, B., & Villard, L. (2019). Clinical and genetic spectrum of basal ganglia calcification disorders. Orphanet Journal of Rare Diseases, 14(1), 234. https://doi.org/10.1186/s13023-019-1182-3
2. Balasubramanian, S., & Crow, Y. J. (2020). Mechanisms of neuroinflammation in mitochondrial and metabolic encephalopathies. Brain Pathology, 30(6), 1047–1062. https://doi.org/10.1111/bpa.12895
3. Brunetti, V., & Scarabino, T. (2021). Diagnostic neuroradiology in rare metabolic encephalopathies. Neuroradiology Journal, 34(5), 415–425. https://doi.org/10.1177/1971400920986058
4. Calvo, S. E., & Mootha, V. K. (2020). The mitochondrial proteome and human disease. Annual Review of Genomics and Human Genetics, 21, 387–410. https://doi.org/10.1146/annurev-genom-111819-095616
5. Ciani, P., & Rizza, F. (2020). Multi-omics systems biology approaches to mitochondrial dysfunction in neurodegeneration. Frontiers in Molecular Neuroscience, 13, 567954. https://doi.org/10.3389/fnmol.2020.567954
6. Crow, Y. J., & Manel, N. (2019). Aicardi-Goutières syndrome and type I interferonopathies: Insights into disease mechanisms. Nature Reviews Immunology, 19(7), 429–440. https://doi.org/10.1038/s41577-019-0151-8
7. DiMauro, S., & Schon, E. A. (2019). Mitochondrial respiratory-chain diseases. New England Journal of Medicine, 371(6),

552–563. https://doi.org/10.1056/NEJMra1401111
8. El-Hattab, A. W., & Scaglia, F. (2021). Mitochondrial cytopathies: Pathogenesis and clinical features. Molecular Genetics and Metabolism, 133(1), 1–15. https://doi.org/10.1016/j.ymgme.2021.03.004
9. Finsterer, J., & Frank, M. (2022). Mitochondrial disorders and neuroimaging biomarkers. Metabolic Brain Disease, 37(1), 25–40. https://doi.org/10.1007/s11011-021-00844-7
10. Frazier, A. E., & Thorburn, D. R. (2021). Biochemical and molecular aspects of mitochondrial respiratory chain disorders. Annual Review of Pathology: Mechanisms of Disease, 16, 57–78. https://doi.org/10.1146/annurev-pathol-031920-093844
11. Garg, S. K., Smith, M., & Singh, P. (2021). Fahr's disease: Mechanisms of brain calcification and new therapeutic targets. Frontiers in Aging Neuroscience, 13, 688842. https://doi.org/10.3389/fnagi.2021.688842
12. Genin, E. C., Bannwarth, S., Lespinasse, F., Ortega-Vila, B., Fragaki, K., Gérard, M., Mauri-Crouzet, A., Moore, D. G., Chaussenot, A., Rouzier, C., Chevrollier, A., Bonneau, D., Reynier, P., & Paquis-Flucklinger, V. (2019). Loss of MICU1 regulation of mitochondrial Ca^{2+} uptake causes a brain and muscle disorder linked to primary mitochondrial disease. Nature Communications, 10(1), 1532. https://doi.org/10.1038/s41467-019-09400-3
13. Goutières, F., Aicardi, J., Barth, P. G., & Lebon, P. (1992). Aicardi-Goutières syndrome: An early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Annals of Neurology, 32(4), 537–541. https://doi.org/10.1002/ana.410320412
14. Haack, T. B., & Prokisch, H. (2020). Mitochondrial diseases: Defects in respiratory chain complexes and beyond. Nature Reviews Molecular Cell Biology, 21(2), 101–117. https://doi.org/10.1038/s41580-019-0170-2
15. Hargreaves, I. P., Sheena, Y., Land, J. M., & Heales, S. J. R. (2005). Glutathione deficiency in patients with mitochondrial disease: Implications for pathogenesis and treatment. Journal of Inherited Metabolic Disease, 28(1), 81–88. https://doi.org/10.1007/s10545-005-5511-2
16. Jiang, H., Zhang, X., & Chen, X. (2020). Basal ganglia calcification in neurodegeneration: Mechanisms and clinical correlations. Neurobiology of Disease, 145, 105056. https://doi.org/10.1016/j.nbd.2020.105056
17. Karaa, A., & Goldstein, A. (2018). Mitochondrial disease: Clinical features, molecular mechanisms, and management. Therapeutic Advances in Neurological Disorders, 11, 1756286418759131. https://doi.org/10.1177/1756286418759131
18. Kato, T., Inoue, T., & Ito, H. (2018). Advanced MRI techniques in mitochondrial and metabolic brain diseases. Japanese Journal of Radiology, 36(7), 405–414. https://doi.org/10.1007/s11604-018-0751-1
19. Khan, A., Khan, H. A., & Azhar, S. (2019). Pathogenic insights and treatment prospects in Leigh syndrome: A mitochondrial disorder. Molecular Genetics and Metabolism, 126(1), 1–12. https://doi.org/10.1016/j.ymgme.2018.12.004
20. Kurian, M. A., & Gissen, P. (2020). Genetic and molecular basis of neurodegenerative basal ganglia disorders. Trends in Neurosciences, 43(1), 20–35. https://doi.org/10.1016/j.tins.2019.10.001
21. Kunz, W. S., & Holt, I. J. (2020). Mitochondrial DNA mutations and their

impact on brain bioenergetics. Brain Research Bulletin, 164, 80–91. https://doi.org/10.1016/j.brainresbull.2020.08.006

22. Lee, J. H., Park, S. J., & Kim, Y. H. (2021). Neuroimaging correlates of metabolic and mitochondrial disorders: A systematic review. NeuroImage: Clinical, 32, 102847. https://doi.org/10.1016/j.nicl.2021.102847
23. Lemos, R. R., Oliveira, M. F., Oliveira, J. R. M., & Santos, T. (2019). Mutations in SLC20A2 and the pathophysiology of primary familial brain calcification. Neuroscience Letters, 707, 134313. https://doi.org/10.1016/j.neulet.2019.134313
24. Li, Y., Jiang, J., & Zhao, C. (2022). Novel ASPA gene variants and genotype-phenotype correlation in Canavan disease: A systematic review. Frontiers in Genetics, 13, 864219. https://doi.org/10.3389/fgene.2022.864219
25. Lin, M. T., & Beal, M. F. (2019). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443(7113), 787–795. https://doi.org/10.1038/nature05292
26. López, L. C., Quinzii, C. M., Area, E., Naini, A., Rahman, S., Schuelke, M., Clarke, C., Hirano, M., & DiMauro, S. (2010). Treatment of mitochondrial disorders: A review of clinical trials. Molecular Genetics and Metabolism, 100(1), 111–117. https://doi.org/10.1016/j.ymgme.2009.12.012
27. Mancuso, M., Filosto, M., & Siciliano, G. (2020). Advances in understanding mitochondrial diseases and therapeutic perspectives. Expert Opinion on Orphan Drugs, 8(2), 59–72. https://doi.org/10.1080/21678707.2020.1716324
28. Nascimento, A. F., Martins, P. R., & Borges, K. (2021). Metabolic reprogramming in mitochondrial disorders: Emerging links with neurodegeneration. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1867(12), 166234. https://doi.org/10.1016/j.bbadis.2021.166234
29. Navarro, C. L., Teixeira, R. C., & Gomes, D. L. (2020). Neuropathological correlates of basal ganglia calcification: From Fahr's syndrome to mitochondrial encephalopathies. Neuropathology, 40(6), 565–577. https://doi.org/10.1111/neup.12700
30. Oliveira, J. R. M., Lemos, R. R., & Santos, T. (2019). Genetic underpinnings of Fahr's disease and mechanisms of abnormal calcium deposition in the brain. Neurogenetics, 20(4), 241–256. https://doi.org/10.1007/s10048-019-00594-8
31. Pérez-Dueñas, B., Serrano, M., & García-Cazorla, A. (2018). Basal ganglia involvement in inherited metabolic disorders: Clinical and imaging aspects. Developmental Medicine & Child Neurology, 60(6), 544–555. https://doi.org/10.1111/dmcn.13704
32. Rahman, S. (2020). Pathophysiology of mitochondrial disease causing epilepsy and status epilepticus. Epilepsy & Behavior, 104(Part B), 106919. https://doi.org/10.1016/j.yebeh.2019.106919
33. Rahman, S., & Rahman, J. (2018). Mitochondrial disease and dysfunction: Molecular insights and emerging therapies. Nature Reviews Neurology, 14(2), 80–100. https://doi.org/10.1038/nrneurol.2017.170
34. Raymond, K., Sébire, G., & Rosa-Neto, P. (2021). Multimodal imaging biomarkers in mitochondrial and metabolic encephalopathies. Frontiers in Neuroscience, 15, 681234. https://doi.org/10.3389/fnins.2021.681234
35. Rossi, M., Ciana, G., & Spagnoli, C. (2022). Fahr's disease: From genetic defects to clinical presentation and management. European Journal of Paediatric Neurology,

36, 56–66. https://doi.org/10.1016/j.ejpn.2022.05.009
36. Ryu, J., & Kim, H. J. (2021). Advances in mitochondrial medicine: Gene therapy and bioenergetic restoration. Frontiers in Cell and Developmental Biology, 9, 655790. https://doi.org/10.3389/fcell.2021.655790
37. Sicca, F., & Balestrini, S. (2021). Neurogenetic spectrum of metabolic and mitochondrial encephalopathies. Journal of Neurology, 268(11), 4081–4096. https://doi.org/10.1007/s00415-021-10525-5
38. Sobrido, M. J., & Geschwind, D. H. (2019). Genetics of primary familial brain calcification. Movement Disorders, 34(12), 1719–1731. https://doi.org/10.1002/mds.27847
39. Tuschl, K., & Mills, P. (2021). Metabolic and genetic mechanisms underlying pediatric mitochondrial encephalopathies. Current Opinion in Pediatrics, 33(6), 657–665. https://doi.org/10.1097/MOP.0000000000001068
40. Valanne, L., & Auranen, M. (2020). Neuroimaging characteristics of Fahr's syndrome and differential diagnosis. European Radiology, 30(7), 3973–3984. https://doi.org/10.1007/s00330-020-06739-2
41. Wang, R., Zhao, Y., & Li, J. (2021). Integrative systems biology approaches in mitochondrial and metabolic brain disorders. Progress in Neurobiology, 201, 102006. https://doi.org/10.1016/j.pneurobio.2021.102006
42. Zschocke, J., & Hoffmann, G. F. (2021). The expanding landscape of metabolic encephalopathies: Diagnostic and therapeutic advances. Journal of Inherited Metabolic Disease, 44(3), 678–690. https://doi.org/10.1002/jimd.12300

HOW TO CITE: Manpreet Singh, Tanmay Ghosh, Kousik Seal, Deepika, Hemlata Bhatt, Ayushi Khali, Varaganti Sai Chitra Prathyusha, Yash Srivastav, Kanumuri Sampangi Bharath*, Converging Mechanisms of Basal Ganglia Calcification, Mitochondrial Dysfunction, and Metabolic Encephalopathy in Fahr's Disease, Canavan Disease, and Leigh Syndrome: A Comparative Review of Pathophysiology, Diagnostic Modalities, and Emerging Therapeutic Strategies in Rare Neurodegeneration, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 11, 1141-1162. https://doi.org/10.5281/zenodo.17518905